arrow
M

Muhammad Furqan

lahore university of management sciences
H指数:26
被引数:3,396

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Synthesis, Identification, and Characterization of a Novel 1,2,5-Selenadiazole Derivative as a Microtubule Targeting Agent That Overcomes Multidrug Resistance

一种新型1,2,5-硒二唑衍生物的合成、鉴定与表征:作为克服多药耐药性的微管靶向剂

2025-09-030
PRE
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

淋巴结靶向、mKRAS特异性的两亲性疫苗在胰腺癌和结直肠癌中的研究:AMPLIFY-201试验1期最终结果

2025-08-110
OAAI
An ILK/STAT3 pathway controls glioblastoma stem cell plasticity

ILK/STAT3通路调控胶质母细胞瘤干细胞可塑性

2024-12-012
OAAI
Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12Cemutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101

Sotorasib (soto)、panitumumab (pani) 和 FOLFIRI 在一线(1L)KRAS G12C突变转移性结直肠癌(mCRC)中的安全性与有效性:CodeBreaK 101的区域性分析

2024-12-010
PRE
Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study

Sotorasib(soto)、panitumumab(pani)和FOLFIRI在KRAS G12C突变型转移性结直肠癌(mCRC)的一线(1L)治疗中的安全性及疗效分析:来自Ib期CodeBreaK 101研究的数据

2024-09-011
PRE
Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages
IMMUNITY
IF26.3
2024-05-011
PRE
Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan

超越临床试验: 约旦免疫治疗对非小细胞肺癌的现实影响

2024-04-300
OAAI
T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine
2024-01-160
PRE
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

胰腺癌和结直肠癌的淋巴结靶向,mKRAS特异性两亲疫苗: 1期扩增201试验

2024-01-0939
OAAI